Schweiger M.W. et al. demonstrated that EVs originating from stem cell-derived glioblastomas can upregulate NF-kB and STAT3 through C/EBPβ, leading to increased aggressiveness and therapeutic resistance, features of the mesenchymal GBM subtype [46]. This evidence concerns the gene NFKB1 and glioblastoma.